Shares of Dilip Buildcon ended 3.3% lower at ₹393.40 on Friday. Previous Post Zydus Lifesciences’ Maharashtra unit clears US FDA inspection with no observations Next Post Glenmark Pharma stages smart recovery in Q3 with ₹348-crore net profit on higher revenues Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
